GlassScriptPhysician profile
Erik Brenner Pikas
NPI 1134650856
$1,080.29
in general payments reported to CMS, 2019-2025
15 companies · $685 in 2025
The $685 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.46 · 2022: $12.74 · 2023: $97.18 · 2024: $264 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $270.56 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Insulet Corporation | $165.37 | 2023-2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.54 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $131.36 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Novo Nordisk INC | $93.65 | 2023-2025 | |
| Dexcom, INC. | $51.76 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $44.58 | 2025 | Abilify Maintena |
| Vertex Pharmaceuticals Incorporated | $39.62 | 2025 | |
| Sumitomo Pharma America, INC. | $28.61 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.55 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $21.46 | 2021 | |
| Merck Sharp & Dohme LLC | $19.72 | 2024 | Vaxelis, M-M-R II, Vaxneuvance |
| Lilly USA, LLC | $18.99 | 2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2025 | |
| Glaxosmithkline, LLC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Pikas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.